BIOGEN INC. Proceeds from (Repayments of) Bank Overdrafts
BIOGEN INC. (BIIB) reported Proceeds from (Repayments of) Bank Overdrafts of $2.82 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfBankOverdrafts · last filed 2012-02-03
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for the quarter ending 2011-12-31 was $5.86M, a 36.32% decline year-over-year.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for the quarter ending 2011-09-30 was -$7.52M.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for the quarter ending 2011-06-30 was $6.95M, a 46.71% increase year-over-year.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for the quarter ending 2011-03-31 was -$2.47M.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for fiscal 2011 was $2.82M, a 76.04% decline from fiscal 2010.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for fiscal 2010 was $11.78M, a 4.02% decline from fiscal 2009.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for fiscal 2009 was $12.28M.
- BIOGEN INC. proceeds from (repayments of) bank overdrafts for fiscal 2008 was -$498.00K.
| Period end | Proceeds from (Repayments of) Bank Overdrafts 3 month | Proceeds from (Repayments of) Bank Overdrafts 6 month | Proceeds from (Repayments of) Bank Overdrafts 9 month | Proceeds from (Repayments of) Bank Overdrafts 12 month |
|---|---|---|---|---|
| 2011-12-31 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | -$1.66M derived: sum of 2 quarters · filed 2012-02-03 | $5.29M derived: sum of 3 quarters · filed 2012-02-03 | $2.82M 10-K · filed 2012-02-03 |
| 2011-09-30 | -$7.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | -$566.00K derived: sum of 2 quarters · filed 2011-10-28 | -$3.03M 10-Q · filed 2011-10-28 | $6.16M derived: sum of 4 quarters · filed 2012-02-03 |
| 2011-06-30 | $6.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $4.49M 10-Q · filed 2011-07-26 | $13.68M derived: sum of 3 quarters · filed 2012-02-03 | $13.35M derived: sum of 4 quarters · filed 2012-02-03 |
| 2011-03-31 | -$2.47M 10-Q · filed 2011-04-21 | $6.73M derived: sum of 2 quarters · filed 2012-02-03 | $6.40M derived: sum of 3 quarters · filed 2012-02-03 | $11.14M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $8.87M derived: sum of 2 quarters · filed 2012-02-03 | $13.61M derived: sum of 3 quarters · filed 2012-02-03 | $11.78M 10-K · filed 2012-02-03 |
| 2010-09-30 | -$326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $4.41M derived: sum of 2 quarters · filed 2011-10-28 | $2.59M 10-Q · filed 2011-10-28 | $7.36M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $2.91M 10-Q · filed 2011-07-26 | $7.69M derived: sum of 3 quarters · filed 2012-02-03 | $7.66M derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | -$1.83M 10-Q · filed 2011-04-21 | $2.95M derived: sum of 2 quarters · filed 2012-02-03 | $2.92M derived: sum of 3 quarters · filed 2012-02-03 | $9.08M derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $4.75M derived: sum of 2 quarters · filed 2012-02-03 | $10.91M derived: sum of 3 quarters · filed 2012-02-03 | $12.28M 10-K · filed 2012-02-03 |
| 2009-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $6.13M derived: sum of 2 quarters · filed 2010-10-26 | $7.50M 10-Q · filed 2010-10-26 | -$11.05M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-06-30 | $6.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $7.53M 10-Q · filed 2010-07-20 | -$11.03M derived: sum of 3 quarters · filed 2011-02-04 | $6.15M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $1.37M 10-Q · filed 2010-04-20 | -$17.18M derived: sum of 2 quarters · filed 2011-02-04 | -$2.00K derived: sum of 3 quarters · filed 2011-02-04 | |
| 2008-12-31 | -$18.55M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | -$1.37M derived: sum of 2 quarters · filed 2011-02-04 | -$498.00K 10-K · filed 2011-02-04 | |
| 2008-09-30 | $17.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $18.05M 10-Q · filed 2009-10-21 | ||
| 2008-06-30 | $873.00K 10-Q · filed 2009-07-17 | |||
| 2007-12-31 | -$5.40M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |